Media Representations of Novel Alzheimer's Disease Treatments: Balancing Benefits and Risks

This study analyzes how major US newspapers portrayed disease-modifying treatments (DMTs) for Alzheimer's disease between 2020-2024, finding that media coverage linked treatment risks primarily to efficacy-to-cost ratios. The research identifies tensions between FDA regulatory challenges, expert disagreement over evidence quality, and patient expectations regarding these novel therapies.